报告期内，公司营业收入较上年同期增加666.65%、营业利润较上年同期亏损收窄33.57%、利润总额较 上年同期亏损收窄32.74%、归属于母公司所有者的净利润较上年同期亏损收窄32.74%，主要系报告期 内公司进一步推动首款商业化产品赛立奇单抗注射液(金立希®)销售市场扩张，产品销售收入较上年同 期稳步增长;同时，GR1803注射液授权许可及商业化协议的合同履约义务所对应的授权许可收入金额较 大，对公司当期净利润产生了积极影响。 智通财经APP讯，智翔金泰(688443.SH)发布2025年度业绩快报，2025年度实现营业总收入2.31亿元，同 比增长666.65%;归属于母公司所有者的净利润亏损5.36亿元，亏损收窄。 ...

Core Viewpoint - The company expects a significant net loss for the year 2025, despite a substantial increase in revenue driven by the sales of its first commercial product and licensing income from a new agreement [1] Financial Performance - The projected net profit attributable to shareholders for 2025 is estimated to be between -480.64 million and -587.45 million yuan [1] - The projected net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be between -523.63 million and -630.44 million yuan [1] - The company reported a substantial increase in operating revenue compared to the same period last year, primarily due to steady sales growth of its commercial product, Glinix® [1] Research and Development - The company maintains a high level of R&D investment as multiple products enter clinical research stages and core products advance to critical clinical trial phases [1] - The company has implemented an equity incentive plan for its core team, which will not incur share-based payment expenses in 2025, leading to a reduction in corresponding costs [1] Overall Outlook - Despite the expected losses for 2025, the company anticipates a significant narrowing of the loss compared to the previous year [1]